Agendia MammaPrint Given Highest Level Evidence Label in Breast Cancer Guidelines

NEW YORK (GenomeWeb) – Agendia said today that its MammaPrint 70-gene signature test that measures risk of recurrence in breast cancer has received the highest medical evidence level 1A label in German Association of Gynecological Oncology (AGO) guidelines for breast cancer care in Germany.

Get the full story This story is free
for registered users

Registering provides access to this and other free content.

Already have an account?
.

Be the first to comment

Leave a Reply

Your email address will not be published.


*